Stock Price Movement and Market Context
On 24 Nov 2025, Valiant Laboratories’ stock recorded an intraday low of Rs.70.26, representing a 3.75% decline on the day and a 3.18% fall in the latest session. This price level also stands as the lowest point the stock has reached in the past year, signalling a notable downtrend. Over the last two trading days, the stock has experienced a cumulative return of -7.89%, underperforming its Pharmaceuticals & Biotechnology sector by 2.56% on the day.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum. This contrasts with the broader market, where the Sensex opened 88.12 points higher and is trading at 85,328.27, just 0.55% shy of its 52-week high of 85,801.70. The Sensex has also been on a three-week consecutive rise, gaining 2.54% in that period, supported by strong performances from mega-cap stocks.
Long-Term Performance and Valuation Metrics
Valiant Laboratories’ one-year stock performance shows a decline of 35.98%, considerably lagging behind the Sensex’s 7.87% gain over the same period. The stock’s 52-week high was Rs.136.80, highlighting the extent of the recent price contraction. Over the past five years, the company’s operating profits have shown a compound annual growth rate (CAGR) of -49.92%, reflecting challenges in sustaining profitability growth.
Financial ratios further illustrate the company’s current position. The average EBIT to interest ratio stands at 0.65, suggesting limited capacity to comfortably cover interest expenses. Return on Equity (ROE) averages at 0.80%, indicating modest profitability relative to shareholders’ funds. Despite this, the stock’s price-to-book value ratio is 1.3, which is relatively elevated given the company’s earnings profile, though it trades at a discount compared to its peers’ historical valuations.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Recent Financial Results and Sales Growth
Despite the stock’s price decline, Valiant Laboratories has reported positive results for the last three consecutive quarters. Net sales for the latest six-month period reached Rs.93.02 crores, reflecting a growth rate of 130.48%. Profit after tax (PAT) for the same period was Rs.2.02 crores, showing an upward trend compared to previous periods.
However, the company’s PEG ratio stands at 0.6, which may reflect the relationship between its price-to-earnings ratio and earnings growth. The stock’s returns over the past year have not aligned with the rise in profits, indicating a disconnect between market valuation and recent financial performance.
Shareholding and Sector Position
Valiant Laboratories operates within the Pharmaceuticals & Biotechnology sector, a space that has seen varied performance across companies. The majority of the company’s shares are held by promoters, which often suggests a stable ownership structure. Nevertheless, the stock’s recent price movements have diverged from the broader sector trends, with the sector itself outperforming the stock on the day.
Holding Valiant Laboratories from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Comparative Market Analysis
When compared to the BSE500 index, Valiant Laboratories has underperformed over multiple time frames, including the last three years, one year, and three months. This underperformance is notable given the broader market’s positive trajectory, particularly the Sensex’s gains and its position above key moving averages. The stock’s relative weakness is further emphasised by its trading below all major moving averages, a technical indicator often associated with bearish trends.
The company’s valuation metrics and financial ratios suggest that the market is pricing in challenges related to profitability and debt servicing capacity. While the company has shown growth in sales and profits recently, these improvements have not yet translated into a recovery in the stock price.
Summary of Key Price and Performance Data
To summarise, Valiant Laboratories’ stock price has reached Rs.70.26, marking a new 52-week and all-time low. The stock has declined by 3.18% on the day and has fallen nearly 8% over the last two sessions. It trades below all significant moving averages and has lagged behind both its sector and the broader market indices. The company’s long-term financial metrics indicate subdued profitability and limited debt coverage capacity, while recent sales and profit figures show some positive trends.
These factors collectively contribute to the current market assessment of Valiant Laboratories, reflected in its stock price performance and valuation levels.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
